Hungary vs Slovenia: Death rate from cancer
Hungary
311.62 deaths per 100,000 people
in 2021
Slovenia
305.17 deaths per 100,000 people
in 2021
Hungary rank
6th
Slovenia rank
8th
Death rate from cancer over time
- Hungary
- Slovenia
How they compare
Hungary currently reports 311.62 deaths per 100,000 people against 305.17 deaths per 100,000 people in Slovenia, a difference of 6.45 deaths per 100,000 people.
Across all 22 years both countries report, Hungary has been ahead every year.
Hungary ranks 6th and Slovenia ranks 8th of 194 countries.
Hungary has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Hungary | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 321.05 deaths per 100,000 people | 263.52 deaths per 100,000 people | 57.54 deaths per 100,000 people | Hungary |
| 2010s | 331.96 deaths per 100,000 people | 297.12 deaths per 100,000 people | 34.84 deaths per 100,000 people | Hungary |
| 2020s | 316.9 deaths per 100,000 people | 306.26 deaths per 100,000 people | 10.64 deaths per 100,000 people | Hungary |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Hungary or Slovenia?
- Hungary, at 311.62 deaths per 100,000 people against 305.17 deaths per 100,000 people in Slovenia as of 2021.
- What is the difference in death rate from cancer between Hungary and Slovenia?
- 6.45 deaths per 100,000 people, with Hungary ahead.
- How many years of comparable data are there for Hungary and Slovenia?
- 22 years are reported by both, from 2000 to 2021.
- How do Hungary and Slovenia rank globally for death rate from cancer?
- Hungary ranks 6th and Slovenia ranks 8th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.